How to Get Tirzepatide in the US

Tirzepatide is one of the few peptides on this site that is unambiguously a normal, FDA-approved prescription drug. That makes “how to get it” a very different question from the one that applies to research peptides like BPC-157 or CJC-1295, where the bottleneck is a tangled compounding situation. With tirzepatide, the legal route is the ordinary one: a licensed provider evaluates you, decides it’s appropriate, and writes a prescription for the brand product that any pharmacy can fill. The friction is almost entirely about which brand matches your diagnosis and how you pay.

This page maps the legal routes, explains the Mounjaro-versus-Zepbound split that trips a lot of people up, and lays out the 2026 pricing landscape at a high level. It does not give dosing instructions or sourcing advice, and it does not cover the clinical decision of whether tirzepatide is right for you — that belongs with a prescriber.

Note: Tirzepatide is the same molecule whether it’s branded Mounjaro or Zepbound. The brand name reflects the FDA-approved indication, not a different drug. This matters enormously for both prescribing and insurance.

What tirzepatide is, briefly

Tirzepatide is a once-weekly injectable that activates two gut-hormone receptors — GIP and GLP-1 — making it the first and only dual GIP/GLP-1 receptor agonist on the US market. That dual action is part of why it has produced some of the strongest weight-reduction and glucose-control results seen in trials for this class of drug.

Eli Lilly makes it and sells it under two brand names with two different labels:

• Mounjaro — FDA-approved in 2022 for type 2 diabetes.
• Zepbound — FDA-approved in 2023 for chronic weight management, with an added indication for moderate-to-severe obstructive sleep apnea in adults with obesity granted in late 2024.

Same active ingredient, same manufacturer, different approved use. For a deeper look at the drug itself, see what is tirzepatide.

The brand split decides almost everything

Before you think about routes or cost, understand the brand question, because it shapes both.

If you have a type 2 diabetes diagnosis, your provider will typically prescribe Mounjaro, and a diabetes diagnosis gives you the best shot at insurance coverage. If you’re seeking treatment for obesity or weight management (or qualifying obstructive sleep apnea), the on-label product is Zepbound. Insurers treat these very differently: many plans that cover Mounjaro for diabetes still exclude Zepbound for weight loss, because weight-management drugs are a common carve-out in US benefit design.

This is the single most important practical fact about getting tirzepatide. The same molecule can be routine and partly covered under one label and a fully out-of-pocket expense under the other. Which one applies to you is a clinical and benefits question, not something you choose off a menu. A head-to-head on the two labels lives at Zepbound vs Mounjaro.

The legal routes, compared

There are three practical legal ways to obtain branded tirzepatide. All of them end the same way — a brand prescription filled by a pharmacy — so the differences are about speed, oversight, and how the visit is structured.

Route 1 — Your own doctor plus a regular pharmacy

The most conventional route. Your primary-care physician, endocrinologist, or obesity-medicine specialist evaluates you, and if appropriate writes a prescription that any retail pharmacy can fill. Because tirzepatide is FDA-approved and no longer in shortage, this is a normal, fillable prescription — no compounding workaround involved.

This route is best when you already have an established relationship with a provider, when you want your tirzepatide managed alongside other conditions, and when you’re pursuing insurance coverage (your doctor’s office can handle prior authorizations and appeals). The trade-off is that some primary-care providers are cautious about weight-management prescribing or want labs and follow-up before committing, which can add time.

Route 2 — Telehealth

Telehealth platforms have become a major access channel for GLP-1-class drugs. A licensed clinician reviews your history (often with intake forms, sometimes a video visit and labs), and if you qualify, sends a prescription to a pharmacy or ships from an affiliated one.

The important 2026 change: reputable telehealth services now prescribe branded tirzepatide rather than compounded versions, because mass-compounded tirzepatide is no longer legal. If a telehealth offer is advertising cheap “compounded tirzepatide” as its main product, treat that as a red flag — see the compounding section below. Telehealth tends to be the fastest mainstream route and convenient if you don’t have an established provider, but it varies in how much ongoing clinical support you get.

Route 3 — In-person weight-loss or diabetes clinic

Dedicated obesity-medicine, endocrinology, or wellness clinics offer in-person evaluation, monitoring, and sometimes bundled labs and visits. This route generally costs more once consults and labs are included, but it gives you hands-on supervision, which some people want when starting an injectable. Vetting matters here as much as anywhere; our guide on how to choose a peptide clinic covers what to check.

For the step-by-step mechanics of the prescription itself — who can prescribe, what an evaluation looks like, and how the script reaches the pharmacy — see tirzepatide prescription: how to get one. The generic version of that process for any peptide is covered at how to get peptides prescribed.

Why “compounded tirzepatide” is no longer a real route

For roughly two years, compounded tirzepatide was widely sold online at a fraction of brand pricing. That window has effectively closed, and understanding why matters because plenty of vendors haven’t updated their messaging.

Compounding of an “essentially a copy” drug is only permitted while the FDA lists that drug as in shortage. Tirzepatide was added to the shortage list in December 2022 amid surging demand. The FDA then determined the shortage resolved in December 2024 and set short wind-down windows: state-licensed pharmacies compounding under section 503A had until roughly mid-February 2025, and 503B outsourcing facilities until mid-March 2025. Courts declined to block those determinations, and the enforcement posture has held since.

The net effect in 2026:

• Mass-produced compounded tirzepatide is illegal. 503B outsourcing facilities lost their authority to compound it once the shortage was declared resolved.
• A narrow 503A exception survives, but only when a prescriber documents a genuine clinical need the commercial product can’t meet — for example, a documented allergy to an inactive ingredient in Mounjaro or Zepbound. Wanting a lower price does not qualify.
• The FDA went further in April 2026, proposing to formally exclude tirzepatide (along with semaglutide and liraglutide) from the 503B bulk drug substances list entirely, with a public comment window running into late June 2026. If finalized, that would foreclose bulk compounding even if a future shortage were ever declared.

The honest summary: for almost everyone, “getting tirzepatide” in 2026 means getting the brand. Anything marketed as cheap compounded tirzepatide outside that narrow individual-need exception is operating in a legal gray-to-red zone, and the FDA has sent a large volume of warning letters to compounders and telehealth marketers in this space. The full regulatory timeline is tracked on compounded GLP-1 legal status, and the 503A-versus-503B framework is explained at compounded peptides: 503A vs 503B.

What it costs — the real wall

With the compounding route gone, cost is where access actually gets decided. Here’s the 2026 landscape at a high level; for a full breakdown see tirzepatide cost, Zepbound cost & access, and Mounjaro cost & access.

• Retail list price for the branded pens runs to roughly a four-figure monthly sum (around $1,000+). Almost nobody who shops carefully pays this.
• With commercial insurance plus the manufacturer savings card, eligible patients can pay as little as about $25/month — but only if the plan covers the relevant brand, which is far more common for Mounjaro (diabetes) than Zepbound (weight loss).
• Self-pay through LillyDirect, Eli Lilly’s own direct-to-consumer pharmacy, is generally the cheapest legal cash route for the brand. Zepbound single-dose vials are tiered by dose, with higher doses capped at a flat monthly rate following a price reduction in early 2026; Mounjaro is sold self-pay through the same platform at its own flat rate. These programs typically require you to refill within a set window to keep the discounted price.
• Pharmacy pickup convenience has improved — self-pay vials can be shipped or picked up at thousands of major retail pharmacy locations.
• Emerging channels: a federal direct-to-consumer purchasing channel has appeared offering branded GLP-1s at a reduced cash price, and Medicare Part D coverage of Zepbound is slated to begin in mid-2026, which would meaningfully change the math for older patients who previously had no covered route.

Two people taking the identical molecule can therefore pay $25 or several hundred dollars a month depending entirely on diagnosis, insurance design, and which program they use. That is the defining feature of tirzepatide access in 2026: the drug is legal and available; affordability is the variable.

Note: Prices, programs, and coverage rules in this space change frequently. Treat any specific figure as current only as of this page’s update date, and confirm directly with the pharmacy, manufacturer program, or your insurer before relying on it.

Which route is right for you?

A rough guide, not medical advice:

• You have type 2 diabetes and insurance: start with your own doctor or an endocrinologist and pursue Mounjaro with a coverage/prior-authorization path. This is usually the cheapest covered route.
• You want weight management and have coverage for it: your provider plus the Zepbound savings card can land you near the lowest tier — if your plan covers weight-loss drugs. Many don’t, so check first.
• You’re paying cash and want the lowest legal price: LillyDirect self-pay for the appropriate brand is generally the floor, with telehealth a convenient way to get the prescription if you don’t have a provider.
• You want close in-person supervision: an obesity-medicine or endocrinology clinic, accepting the higher all-in cost.

Whichever route you choose, the destination is the same legitimate one: an FDA-approved brand product, prescribed after a real evaluation, filled by a licensed pharmacy. For a side-by-side with the other dominant weight-loss peptide, see how to get semaglutide and the clinical comparison at semaglutide vs tirzepatide.

The bottom line

Getting tirzepatide legally in the US in 2026 is, mechanically, simple: it’s an approved drug, so a prescriber writes a normal prescription for Mounjaro or Zepbound and a pharmacy fills it. The complexity lives elsewhere — in matching your diagnosis to the right brand, in navigating insurance rules that treat diabetes and weight loss differently, and in choosing among self-pay programs to manage cost. The compounded shortcut that defined the past few years is, for nearly everyone, no longer a legal option.